Sulzer Medica Entering Peripheral Stent Market Via IntraTherapeutics
This article was originally published in The Gray Sheet
Executive Summary
Sulzer Medica's $145 mil. purchase of privately held IntraTherapeutics provides the firm an entry into the $300 mil. peripheral stent market and complements Sulzer's heart valve and vascular graft businesses.